search

Active clinical trials for "Death, Sudden, Cardiac"

Results 191-200 of 257

The Ability Of The PD2i Cardiac Analyzer To Predict Risk Of Ventricular Tachyarrhythmic Events

TachycardiaVentricular1 more

This is a prospective study to evaluating the ability of the PD2i Cardiac Analyzer to predict the risk of serious heart rhythm abnormalities in high-risk patients that do not already have an Implantable Cardioverter Defibrillator.

Withdrawn12 enrollment criteria

Analyzing Gene Regions That May Interact With the Effectiveness of High Blood Pressure Drugs

Myocardial InfarctionCerebrovascular Accident3 more

High blood pressure is one of the most common health problems in the United States. There are many drug treatment options for high blood pressure, but these medications are not always effective. People with treated high blood pressure can still suffer from other serious cardiovascular health problems, including heart attack, sudden death, or stroke. Genetic variations may cause some people to be more susceptible to these cardiovascular outcomes despite treatment. This study will identify new gene regions that may influence the effectiveness of high blood pressure drugs in preventing the above mentioned cardiovascular conditions.

Withdrawn4 enrollment criteria

Influence of the Education in Layperson in Out of Hospital Resuscitation

Cardiac ArrestSudden1 more

Cardiac arrest occurs frequently and the outcome after out-of-hospital resuscitation is often fatal. Disturbing is that more than half of the surviving patients suffer from permanent impairment of cognitive functions, such attention, memory and executive functioning. With all the efforts to achieve a high quality initial resuscitation management the time delay between cardiac arrest and the beginning the initial resuscitation maneuver is the main reason for the still poor outcome. To shorten this fatal time delay, current efforts of national and supranational health authorities aime at the non-medically trained lay person, who should carry out basic life support directly on the scene supported by the use of public available semi-automatic defibrillators (AED).

Completed5 enrollment criteria

Sudden Cardiac Death in Systemic Right Ventricle

Sudden Cardiac DeathCongenital Heart Disease1 more

In complete transposition of the great arteries (TGA) with previous atrial switch repair, and congenitally corrected transposition of the great arteries (ccTGA), the morphological right ventricle and its tricuspid valve continue to support the systemic circulation. This results in late complications including including sudden death. This retrospective multicentric study aims to evaluate the prevalence of SCD in a contemporary population of patients with a systemic RV and identify specific risk factors for SCD and hemodynamically significant ventricular arrhythmia This registry records demographics, clinical, imaging data, electrophysiological and laboratory of patients with a sRV and a transposition of the great arteries Primary end points are defined by sudden cardiac death, near-miss sudden death, as well as sustained VT requiring defibrillation.

Completed2 enrollment criteria

Medtronic Genetic Arrhythmia Markers for Early Detection (GAME Study)

DeathSudden5 more

To generate a list of potential genetic markers that correlate with an increased risk of life-threatening arrhythmias. To evaluate ECG-based risk markers such as heart rate variability and T-wave Alternans for their association with arrhythmic events.

Completed23 enrollment criteria

Morphological Predictors of Sudden Cardiac Death in Patients With Known Cardiomyopathies

Cardiomyopathy

This is a pilot study to find a correlation between MRI and ICD therapy in patients with known cardiomyopathies, aiming to determine if cardiac scarring identified by MRI correlates with ventricular arrhythmias and the occurrence of ICD therapy.

Completed8 enrollment criteria

In-hospital Cardiac Arrest - Dynamics and State Transitions

Heart ArrestDeath2 more

The purpose of this study is to analyse transitions in cardiac rhythm and hemodynamic variables during resuscitation of patients with in-hospital cardiac arrest.

Completed2 enrollment criteria

Genetic Determinants of Sudden Cardiac Death

Cardiovascular DiseasesHeart Diseases5 more

To evaluate whether genetic variation in selected candidate genes is associated with risk of sudden cardiac death in the general population.

Completed1 enrollment criteria

Natural History of Coronary Heart Disease

Cardiovascular DiseasesCoronary Disease8 more

To examine the natural history of mortality due to coronary heart disease in post-myocardial infarction patients from the Beta-Blocker Heart Attack Trial (BHAT) and the Aspirin Myocardial Infarction Study (AMIS).

Completed1 enrollment criteria

Blood Management During ECMO for Cardiac Support

DeathSudden11 more

Extracorporeal membrane oxygenation (ECMO) is a lifesaving procedure used to treat severe forms of heart and/or lung failure. It works by the principal of replacing the function of these organs by taking blood from the patient, provide it with oxygen outside the body and return it to the patient in one continuous circuit. Because of the evaluability of better technology, the use of ECMO has exponentially risen over the last decade. This treatment is very invasive and carries a number of risks. It is mostly used in situations where it seems likely that the patient would otherwise die and no other less invasive measure could change this. Still in large registries 50-60% of patients die which is often due to complications associated with the treatment. One of the most important complication is caused by the activation of clotting factors during the contact with the artificial surfaces of the device. This can lead to clot formation inside the patient or the device. To counterbalance this anticoagulation is needed. Because of the consumption of clotting factors and the heparin therapy bleeding complications are also very common in ECMO. Clinicians are challenged to balance these competing risks and are often forced to transfuse blood products to treat these conditions, which comes with additional risks for the patient. Many experienced centres have reported thromboembolic and bleeding events as the most important contributor to a poor outcome of this procedure. However, no international study combining the experience of multiple centres to compare their practice and identify risk factors which can be altered to reduce these risks. This study has been endorsed by the international ECMONet and aims to observe the practice in up to 50 centres and 500 patients worldwide to generate the largest ever published database on this topic. It will concentrate on patients with severe heart failure and will be able to identify specific risk factors for thromboembolic and bleeding events. Some of these factors may be modifiable by change in practice and can subsequently be evaluated in clinical trials. Some of these factors may include target values for heparin therapy and infusion of clotting factors. This study will directly improve patient management by informing clinicians which measures are associated with the best outcome and indirectly helps building trials to increase the evidence further.

Completed8 enrollment criteria
1...192021...26

Need Help? Contact our team!


We'll reach out to this number within 24 hrs